Medical Center Nadezhda Clinical EOOD

Verified siteinfo

Bulgaria Blaga Vest Str 3, 1303 Sofia, Bulgaria

1 trial recruiting
Breast cancer · Non-small cell lung cancer · Ovarian cancer
Adults and children

About Specializations

Medical Center Nadezhda Clinical EOOD in Sofia, Bulgaria specialises in clinical trials of conditions such as Breast cancer, Non-small cell lung cancer, Ovarian cancer, Central nervous system melanoma, and other specialisations. This site conducts important research.

Main research areas of the site

Oncology

The medical center is at the forefront of oncology research, with a particular focus on melanoma treatment. The institution is actively involved in exploring innovative therapies for metastatic or unresectable locally advanced BRAF V600E/K mutation-positive melanoma.

Targeted Therapy
Immunotherapy
Combination Treatments

Through its research, the center is contributing to the development of advanced therapeutic strategies that aim to improve patient outcomes and enhance the efficacy of existing treatments.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

Blaga Vest Str 31303 SofiaBulgaria

Open in maps ↗

Recruiting now: 1 trial
Conditions studied: 17
Partner status: Verified site

More sites in Sofia Bulgaria

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Quick filters

8 clinical trials

Endometrial cancer+5

Recruiting

Study for Patients with BRCA Mutated Ovarian, Breast, Pancreatic, Prostate, and Endometrial Cancers Continuing Olaparib Treatment

Registered drugNo placebo

Study for Patients with BRCA Mutated Ovarian, Breast, Pancreatic, Prostate, and Endometrial Cancers Continuing Olaparib Treatment

Registered drugNo placebo

Bulgaria

Participants:18–64 years · 65+ years
Substances:Olaparib
Sponsor:AstraZeneca AB

Contact Research Centre

Breast cancer+1

Not yet recruiting

Long‑term safety study of alpelisib alone or with fulvestrant in adults with breast cancer who benefited from previous alpelisib treatment

Registered drugNo placebo

Long‑term safety study of alpelisib alone or with fulvestrant in adults with breast cancer who benefited from previous alpelisib treatment

Registered drugNo placebo

Bulgaria

Participants:0–17 years · 18–64 years · 65+ years
Substances:Alpelisib
Sponsor:Novartis Pharma AG

Contact Research Centre

Ovarian cancer

Not recruiting

Study on the Effectiveness of Durvalumab, Olaparib, and Bevacizumab in Patients with Newly Diagnosed Advanced Ovarian Cancer

Registered drug

Study on the Effectiveness of Durvalumab, Olaparib, and Bevacizumab in Patients with Newly Diagnosed Advanced Ovarian Cancer

Registered drug

Bulgaria

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:AstraZeneca AB

Contact Research Centre

Breast cancer

Not recruiting

Study of Camizestrant and CDK4/6 Inhibitor for Patients with Advanced Breast Cancer with ESR1 Mutation

Registered drug

Study of Camizestrant and CDK4/6 Inhibitor for Patients with Advanced Breast Cancer with ESR1 Mutation

Registered drug

Bulgaria

Participants:18–64 years · 65+ years
Substances:Abemaciclib
Sponsor:AstraZeneca AB

Contact Research Centre

Gastrointestinal melanoma+7

Not recruiting

Study of Encorafenib, Binimetinib, and Pembrolizumab for Patients with Advanced Melanoma with BRAF V600E/K Mutation

Registered drug

Study of Encorafenib, Binimetinib, and Pembrolizumab for Patients with Advanced Melanoma with BRAF V600E/K Mutation

Registered drug

Bulgaria

Participants:18–64 years · 65+ years
Substances:Binimetinib
Sponsor:Pfizer Inc.

Contact Research Centre

Non-small cell lung cancer

Not recruiting

Study of Datopotamab Deruxtecan, Durvalumab, and Carboplatin for Advanced Non-Small Cell Lung Cancer in Patients Without Actionable Genomic Alterations

Registered drugNo placebo